389 related articles for article (PubMed ID: 24262196)
41. Proteasome inhibition induces α-synuclein SUMOylation and aggregate formation.
Kim YM; Jang WH; Quezado MM; Oh Y; Chung KC; Junn E; Mouradian MM
J Neurol Sci; 2011 Aug; 307(1-2):157-61. PubMed ID: 21641618
[TBL] [Abstract][Full Text] [Related]
42. [Parkinson's disease, dementia with Lewy bodies, multiple system atrophy and alpha-synuclein].
Iwatsubo T
Rinsho Shinkeigaku; 1999 Dec; 39(12):1285-6. PubMed ID: 10791099
[TBL] [Abstract][Full Text] [Related]
43. Immunotherapeutic interventions in Parkinson's disease: Focus on α-Synuclein.
Ganguly U; Singh S; Chakrabarti S; Saini AK; Saini RV
Adv Protein Chem Struct Biol; 2022; 129():381-433. PubMed ID: 35305723
[TBL] [Abstract][Full Text] [Related]
44. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death.
Volpicelli-Daley LA; Luk KC; Patel TP; Tanik SA; Riddle DM; Stieber A; Meaney DF; Trojanowski JQ; Lee VM
Neuron; 2011 Oct; 72(1):57-71. PubMed ID: 21982369
[TBL] [Abstract][Full Text] [Related]
45. Unbiased Proteomics of Early Lewy Body Formation Model Implicates Active Microtubule Affinity-Regulating Kinases (MARKs) in Synucleinopathies.
Henderson MX; Chung CH; Riddle DM; Zhang B; Gathagan RJ; Seeholzer SH; Trojanowski JQ; Lee VMY
J Neurosci; 2017 Jun; 37(24):5870-5884. PubMed ID: 28522732
[TBL] [Abstract][Full Text] [Related]
46. Α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration.
Tran HT; Chung CH; Iba M; Zhang B; Trojanowski JQ; Luk KC; Lee VM
Cell Rep; 2014 Jun; 7(6):2054-65. PubMed ID: 24931606
[TBL] [Abstract][Full Text] [Related]
47. Three-layered structure shared between Lewy bodies and lewy neurites-three-dimensional reconstruction of triple-labeled sections.
Kanazawa T; Uchihara T; Takahashi A; Nakamura A; Orimo S; Mizusawa H
Brain Pathol; 2008 Jul; 18(3):415-22. PubMed ID: 18394008
[TBL] [Abstract][Full Text] [Related]
48. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
Schulz-Schaeffer WJ
Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
[TBL] [Abstract][Full Text] [Related]
49. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
Lee VM; Trojanowski JQ
Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
[TBL] [Abstract][Full Text] [Related]
50. α-Synuclein in Parkinson's Disease: Does a Prion-Like Mechanism of Propagation from Periphery to the Brain Play a Role?
Zheng H; Shi C; Luo H; Fan L; Yang Z; Hu X; Zhang Z; Zhang S; Hu Z; Fan Y; Yang J; Mao C; Xu Y
Neuroscientist; 2021 Aug; 27(4):367-387. PubMed ID: 32729773
[TBL] [Abstract][Full Text] [Related]
51. Parkinson's disease.
Mhyre TR; Boyd JT; Hamill RW; Maguire-Zeiss KA
Subcell Biochem; 2012; 65():389-455. PubMed ID: 23225012
[TBL] [Abstract][Full Text] [Related]
52. Alpha-Synuclein: Mechanisms of Release and Pathology Progression in Synucleinopathies.
Brás IC; Outeiro TF
Cells; 2021 Feb; 10(2):. PubMed ID: 33673034
[TBL] [Abstract][Full Text] [Related]
53. α-Synuclein Propagation Mouse Models of Parkinson's Disease.
Uemura N; Ueda J; Okuda S; Sawamura M; Takahashi R
Methods Mol Biol; 2021; 2322():119-130. PubMed ID: 34043198
[TBL] [Abstract][Full Text] [Related]
54. Behavioral defects associated with amygdala and cortical dysfunction in mice with seeded α-synuclein inclusions.
Stoyka LE; Arrant AE; Thrasher DR; Russell DL; Freire J; Mahoney CL; Narayanan A; Dib AG; Standaert DG; Volpicelli-Daley LA
Neurobiol Dis; 2020 Feb; 134():104708. PubMed ID: 31837424
[TBL] [Abstract][Full Text] [Related]
55. Mass Spectrometric Analysis of Lewy Body-Enriched α-Synuclein in Parkinson's Disease.
Bhattacharjee P; Öhrfelt A; Lashley T; Blennow K; Brinkmalm A; Zetterberg H
J Proteome Res; 2019 May; 18(5):2109-2120. PubMed ID: 30943367
[TBL] [Abstract][Full Text] [Related]
56. ɑ-Synuclein strains and seeding in Parkinson's disease, incidental Lewy body disease, dementia with Lewy bodies and multiple system atrophy: similarities and differences.
Peelaerts W; Bousset L; Baekelandt V; Melki R
Cell Tissue Res; 2018 Jul; 373(1):195-212. PubMed ID: 29704213
[TBL] [Abstract][Full Text] [Related]
57. Pathological biochemistry of alpha-synucleinopathy.
Iwatsubo T
Neuropathology; 2007 Oct; 27(5):474-8. PubMed ID: 18018483
[TBL] [Abstract][Full Text] [Related]
58. A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation.
Meredith GE; Halliday GM; Totterdell S
Parkinsonism Relat Disord; 2004 Jun; 10(4):191-202. PubMed ID: 15120093
[TBL] [Abstract][Full Text] [Related]
59. A deadly spread: cellular mechanisms of α-synuclein transfer.
Steiner JA; Angot E; Brundin P
Cell Death Differ; 2011 Sep; 18(9):1425-33. PubMed ID: 21566660
[TBL] [Abstract][Full Text] [Related]
60. [Clinical and pathological study on early diagnosis of Parkinson's disease and dementia with Lewy bodies].
Orimo S
Rinsho Shinkeigaku; 2008 Jan; 48(1):11-24. PubMed ID: 18386627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
